TNF Label Arms Race: Enbrel And Remicade Add Indications
Executive Summary
FDA has upgraded the rheumatoid arthritis indication for J&J's Remicade (infliximab) to first-line use based on a trial in patients with early disease
You may also be interested in...
TNF Inhibitor Prescribing For RA Nearly Doubles, Caremark Exec Says
Treatment regimens for the tumor necrosis factor-alpha inhibitors Abbott's Humira (adalimumab) and Johnson & Johnson's Remicade (infliximab) may be becoming increasingly aggressive
TNF Inhibitor Prescribing For RA Nearly Doubles, Caremark Exec Says
Treatment regimens for the tumor necrosis factor-alpha inhibitors Abbott's Humira (adalimumab) and Johnson & Johnson's Remicade (infliximab) may be becoming increasingly aggressive
J&J’s Remicade Adds Hematologic, Neurologic Warnings To Label
Johnson & Johnson's TNF-inhibitor Remicade has added warnings for hematologic and neurologic events to its label